Chemotherapy after liver surgery for colorectal cancer that spread to the liver
Part of Cancer, Digestive system clinical trials.
This trial tests giving patients a type of chemotherapy called FOLFIRI after they have had surgery to remove colorectal cancer that spread to the liver. The goal is to see if this additional treatment helps prevent the cancer from coming back, for patients who could not have a different chemotherapy before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had liver surgery to remove colorectal cancer that came back more than 12 months after your original treatment.
- You had at least 2 and up to 8 rounds of FOLFIRI chemotherapy before your surgery, along with or without targeted therapy.
- Your last round of this pre-surgery chemotherapy was within 12 weeks before your surgery.
- Your surgery removed all visible liver disease, and any remaining small spots were treated with radiofrequency ablation (a heat probe) if needed.
- Your cancer responded to the pre-surgery chemotherapy, either by shrinking on scans or showing major response under the microscope, or it stayed stable.
- You are 18 or older, generally active (able to do light work), and have no other health conditions that would make this chemotherapy unsafe.
- You are not pregnant or breastfeeding, and you do not have certain genetic conditions that make chemotherapy risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy directly into the liver after surgery can lower the chance of cancer coming back. It is for people who had multiple liver tumors removed and whose cancer did not grow during pre-surgery chemo.
This trial checks whether giving chemotherapy after surgery only for people whose blood test (ctDNA) shows no remaining cancer can help prevent the cancer from coming back. It is for people with colon cancer that has spread to the liver who had the tumor fully removed.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This Phase 3 trial studies a treatment approach for people whose colorectal cancer has come back in the liver within 12 months and can be treated with local procedures. It aims to see whether the study treatment can improve outcomes compared with standard care for people with a limited number of liver tumors.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.